1Laboratory of Mammary Pathology, Department of Anatomical Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
2Department of Surgery, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
3Department of Medical Clinic, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
4Institute of Teaching and Research of Santa Casa de Belo Horizonte, Belo Horizonte, Brazil
Copyright © 2024 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical Statement
This is a retrospective cohort study, approved by the Research Ethics Committee of the Federal University of Minas Gerais (COEPUFMG) under protocol # 2.109.565. Given the retrospective nature of the study, no informed consent was required from the research ethics committee.
Author Contributions
Conceived and designed the analysis: Santos BJ, Balabram D, Nunes CB.
Collected the data: Santos BJ, Gomes VMR, Castro CCC, Nunes CB.
Contributed data or analysis tools: Santos BJ, Balabram D, Diniz PH, Nunes CB.
Performed the analysis: Santos BJ, Balabram D, Buzelin MA, Nunes CB.
Wrote the paper: Santos BJ, Balabram D, Nunes CB.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Parameter | No. (%) | No. of events (%) | Hazard ratio (95% CI) | p-valuea) |
---|---|---|---|---|
Age (yr), mean±SD | 49.65±11.40 | - | 0.98 (0.96-1.00) | 0.046 |
Stage | ||||
II | 13 (15.1) | 10 (76.9) | 1 | - |
III | 57 (66.3) | 40 (70.2) | 0.94 (0.47-1.89) | 0.864 |
IV | 12 (14.0) | 9 (75.0) | 1.29 (0.52-3.19) | 0.586 |
Missing | 4 (4.7) | |||
Tumor size | ||||
1 | 2 (2.3) | 2 (100) | 1 | - |
2 | 12 (14.0) | 9 (75.0) | 0.59 (0.12-2.74) | 0.497 |
3 | 26 (30.2) | 18 (69.2) | 0.69 (0.16-3.00) | 0.622 |
4 | 42 (48.8) | 30 (71.4) | 0.63 (0.15-2.64) | 0.525 |
Missing | 4 (4.7) | |||
Positive lymph nodes | ||||
0 | 8 (9.3) | 7 (87.5) | 1 | - |
1 | 31 (36.0) | 20 (64.5) | 0.56 (0.23-1.33) | 0.189 |
2 | 40 (46.5) | 30 (75.0) | 0.64 (0.28-1.48) | 0.302 |
3 | 3 (3.5) | 2 (66.7) | 0.90 (0.19-4.36) | 0.899 |
Missing | 4 (4.7) | |||
Distant metastasis | ||||
0 | 70 (81.4) | 50 (71.4) | 1.35 (0.66-2.74) | 0.408 |
1 | 12 (14.0) | 9 (75.0) | ||
Missing | 4 (4.7) | |||
Residual Cancer Burden Class | ||||
I | 1 (1.2) | 0 | 0.00 (0.00-5.18) | 0.972 |
II | 30 (30.4) | 17 (56.7) | 0.62 (0.35-1.09) | 0.098 |
III | 54 (64.0) | 44 (81.5) | 1 | |
NACT | ||||
Doxorubicin/Cyclophosphamide+taxane | 60 (69.8) | 40 (66.7) | 1 | - |
Doxorubicin/Cyclophosphamide | 10 (11.6) | 7 (70.0) | 0.94 (0.42-2.12) | 0.891 |
Others | 12 (18.6) | 11 (91.7) | 2.93 (1.48-5.79) | 0.002 |
Missing | 4 (0.1) |
Parameter | Pre-NACT samples No. (%) | Post-NACT samples No. (%) | Pre and post-NACT p-valuea) |
Pre-NACT survival |
Post-NACT survival |
||||
---|---|---|---|---|---|---|---|---|---|
No. of events (%) | Hazard ratio (95% CI) | p-valuea) | No. of events (%) | Hazard ratio (95% CI) | p-valuea) | ||||
Histological type | |||||||||
Ductal NST | 63 (73.3) | 52 (60.5) | 0.392 | 47 (75.8) | 1 | - | 36 (70.6) | 1 | - |
Invasive lobular carcinoma | 7 (8.1) | 5 (5.8) | 3 (42.9) | 0.38 (0.12-1.24) | 0.109 | 4 (80.0) | 0.93 (0.33-2.62) | 0.886 | |
Other special types | 16 (18.6) | 21 (24.4) | 11 (68.7) | 0.94 (0.49-1.82) | 0.856 | 17 (81.0) | 1.32 (0.74-2.35) | 0.349 | |
Isolated cells only | 0 | 8 (9.3) | - | - | - | 4 (50.0) | 0.60 (0.21-1.69) | 0.331 | |
Histological grade | |||||||||
I | 15 (17.4) | 6 (7.0) | 0.115 | 8 (53.3) | 1 | - | 3 (50.0) | 1 | - |
II | 29 (33.7) | 31 (36.0) | 20 (69.0) | 1.91 (0.84-4.38) | 0.124 | 21 (72.4) | 1.96 (0.58-6.60) | 0.275 | |
III | 42 (48.8) | 41 (47.7) | 33 (80.5) | 2.94 (1.35-6.39) | 0.007 | 33 (82.5) | 2.98 (0.91-9.75) | 0.071 | |
Not evaluable | 0 | 8 (9.3) | - | - | - | - | |||
Tubule formation score | |||||||||
1 | 4 (4.7) | 2 (2.3) | 0.189 | 2 (50.0) | 1 | - | 1 (50.0) | 1 | - |
2 | 10 (11.6) | 17 (19.8) | 6 (60.0) | 1.33 (0.27-6.58) | 0.730 | 10 (58.8) | 1.83 (0.23-14.32) | 0.566 | |
3 | 72 (83.7) | 59 (68.6) | 53 (74.6) | 2.16 (0.52-8.89) | 0.286 | 46 (79.3) | 3.69 (0.50-26.90) | 0.198 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Nuclear pleomorphism score | |||||||||
1 | 10 (11.6) | 2 (2.3) | 0.025 | 6 (60.0) | 1 | - | 0 | 1 | - |
2 | 23 (26.7) | 20 (23.3) | 15 (65.2) | 1.70 (0.66-4.40) | 0.373 | 13 (65.0) | - (0.00-∞) | 0.889 | |
3 | 53 (61.6) | 56 (65.1) | 40 (76.9) | 2.53 (1.06-6.00) | 0.036 | 44 (78.6) | - (0.00-∞) | 0.881 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Mitotic count score | |||||||||
1 | 35 (40.7) | 32 (38.4) | 0.002 | 22 (62.9) | 1 | - | 21 (65.6) | 1 | - |
2 | 25 (29.1) | 16 (17.4) | 19 (79.2) | 2.26 (1.21-4.24) | 0.011 | 13 (81.2) | 2.12 (1.04-4.30) | 0.038 | |
3 | 26 (30.2) | 30 (34.9) | 20 (76.9) | 1.65 (0.89-3.03) | 0.109 | 23 (79.3) | 1.48 (0.81-2.67) | 0.199 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Tumor infiltrating inflammatory cells (%) | |||||||||
0 | 13 (15.1) | 25 (29.1) | 0.016 | 10 (76.9) | 1 | - | 18 (72.0) | 1 | - |
1 to 20 | 55 (64.0) | 49 (57.0) | 39 (70.9) | 0.83 (0.42-1.69) | 0.620 | 32 (65.3) | 0.87 (0.49-1.57) | 0.656 | |
≥ 21 | 18 (20.9) | 12 (14.0) | 12 (70.6) | 0.85 (0.37-1.98) | 0.715 | 11 (92.0) | 1.32 (0.59-2.95) | 0.503 | |
Associated in situ carcinoma | |||||||||
Present | 11 (12.8) | 29 (33.7) | < 0.001 | 5 (45.5) | 0.42 (0.17-1.07) | 0.068 | 20 (69.0) | 1.11 (0.66-1.88) | 0.682 |
Absent | 75 (87.2) | 57 (66.3) | 56 (75.7) | 41 (71.9) | |||||
Lymphovascular invasion | |||||||||
Present | 24 (27.9) | 44 (51.2) | 0.002 | 17 (70.8) | 1.26 (0.71-2.23) | 0.422 | 36 (81.8) | 1.90 (1.12-3.19) | 0.016 |
Absent | 62 (72.1) | 42 (48.8) | 44 (72.1) | 25 (61.0) | |||||
Estrogen receptor status | |||||||||
Negative | 38 (44.2) | 49 (57.0) | 0.003 | 32 (86.5) | 0.35 (0.21-0.58) | < 0.001 | 40 (83.3) | 0.39 (0.23-0.67) | < 0.001 |
Positive | 48 (55.8) | 37 (43.0) | 29 (60.4) | 21 (56.8) | |||||
Progesterone receptor status | |||||||||
Negative | 46 (53.5) | 57 (66.3) | 0.019 | 38 (84.4) | 0.37 (0.20-0.63) | < 0.001 | 43 (76.8) | 0.57 (0.32-0.98) | 0.044 |
Positive | 40 (46.5) | 29 (33.7) | 23 (57.5) | 18 (62.1) | |||||
HER2 expression | |||||||||
Negative | 75(87.2) | 76 (88.4) | 0.051 | 54 (73.0) | 1.08 (0.49-2.38) | 0.842 | 54 (72.0) | 1.21 (0.55-2.67) | 0.632 |
Positive | 11(12.8) | 10 (11.6) | 7 (63.6) | 7 (70.0) | |||||
Ki67 expression | |||||||||
Low | 44 (51.2) | 62 (72.1) | 0.003 | 26 (60.5) | 2.47 (1.47-4.15) | 0.001 | 41 (66.1) | 1.68 (0.98-2.87) | 0.06 |
High | 42 (48.8) | 24 (27.9) | 35 (83.3) | 20 (87.0) | |||||
IHC profile | |||||||||
Luminal A–like | 18 (20.9) | 26 (30.2) | < 0.001 | 10 (55.6) | 1 | - | 11 (42.3) | 1 | - |
Luminal B–like | 30 (34.9) | 12 (14.0) | 19 (63.3) | 1.12 (0.57-2.65) | 0.595 | 10 (83.3) | 2.58 (1.09-6.13) | 0.031 | |
HER2-positive | 7 (8.1) | 6 (7.0) | 4 (57.1) | 1.25 (0.39-4.01) | 0.712 | 3 (50.0) | 2.03 (0.56-7.30) | 0.279 | |
Triple-negative | 31 (36.0) | 42 (48.8) | 28 (93.3) | 4.45 (2.12-9.32) | < 0.001 | 37 (88.1) | 4.52 (2.29-8.92) | < 0.001 |
Survival analysis refers to the 85 cases with available survival data. CI, confidence interval; Ductal NST, invasive carcinoma of no special type; HER2, human epidermal growth factor receptor 2; IHC profile, immunohistochemmichal profile; NACT, neoadjuvant chemotherapy.
a) p-value calculated by Mc-Nemar, Mc-Nemar-Bowker, Wilcoxon and Cox proportional hazards model.
Included parameter |
Final step |
|
---|---|---|
HR (95% CI) | p-valuea) | |
Pre-NACT | ||
Age at diagnosis | - | - |
Histological grade | ||
I | 1 | - |
II | 1.87 (0.79-4.39) | 0.152 |
III | 2.71 (1.16-6.31) | 0.021 |
IHC profile | ||
Luminal A-like | 1 | - |
Luminal B-like | 0.91 (0.41-2.04) | 0.823 |
HER2-like | 0.73 (0.21-2.50) | 0.618 |
Triple-negative | 3.32 (1.52-7.27) | 0.003 |
Post-NACT | ||
Age at diagnosis | - | - |
Presence of lymphovascular invasion | - | - |
Histological grade | ||
I | - | - |
II | - | - |
III | - | - |
IHC profile | ||
Luminal A–like | 1 | - |
Luminal B–like | 2.26 (0.95-5.35) | 0.065 |
HER2-like | 2.06 (0.45-9.35) | 0.349 |
Triple-negative | 4.39 (2.20-8.77) | < 0.001 |
Parameter | No. (%) | No. of events (%) | Hazard ratio (95% CI) | p-value |
---|---|---|---|---|
Age (yr), mean±SD | 49.65±11.40 | - | 0.98 (0.96-1.00) | 0.046 |
Stage | ||||
II | 13 (15.1) | 10 (76.9) | 1 | - |
III | 57 (66.3) | 40 (70.2) | 0.94 (0.47-1.89) | 0.864 |
IV | 12 (14.0) | 9 (75.0) | 1.29 (0.52-3.19) | 0.586 |
Missing | 4 (4.7) | |||
Tumor size | ||||
1 | 2 (2.3) | 2 (100) | 1 | - |
2 | 12 (14.0) | 9 (75.0) | 0.59 (0.12-2.74) | 0.497 |
3 | 26 (30.2) | 18 (69.2) | 0.69 (0.16-3.00) | 0.622 |
4 | 42 (48.8) | 30 (71.4) | 0.63 (0.15-2.64) | 0.525 |
Missing | 4 (4.7) | |||
Positive lymph nodes | ||||
0 | 8 (9.3) | 7 (87.5) | 1 | - |
1 | 31 (36.0) | 20 (64.5) | 0.56 (0.23-1.33) | 0.189 |
2 | 40 (46.5) | 30 (75.0) | 0.64 (0.28-1.48) | 0.302 |
3 | 3 (3.5) | 2 (66.7) | 0.90 (0.19-4.36) | 0.899 |
Missing | 4 (4.7) | |||
Distant metastasis | ||||
0 | 70 (81.4) | 50 (71.4) | 1.35 (0.66-2.74) | 0.408 |
1 | 12 (14.0) | 9 (75.0) | ||
Missing | 4 (4.7) | |||
Residual Cancer Burden Class | ||||
I | 1 (1.2) | 0 | 0.00 (0.00-5.18) | 0.972 |
II | 30 (30.4) | 17 (56.7) | 0.62 (0.35-1.09) | 0.098 |
III | 54 (64.0) | 44 (81.5) | 1 | |
NACT | ||||
Doxorubicin/Cyclophosphamide+taxane | 60 (69.8) | 40 (66.7) | 1 | - |
Doxorubicin/Cyclophosphamide | 10 (11.6) | 7 (70.0) | 0.94 (0.42-2.12) | 0.891 |
Others | 12 (18.6) | 11 (91.7) | 2.93 (1.48-5.79) | 0.002 |
Missing | 4 (0.1) |
Parameter | Pre-NACT samples No. (%) | Post-NACT samples No. (%) | Pre and post-NACT p-value |
Pre-NACT survival |
Post-NACT survival |
||||
---|---|---|---|---|---|---|---|---|---|
No. of events (%) | Hazard ratio (95% CI) | p-value |
No. of events (%) | Hazard ratio (95% CI) | p-value |
||||
Histological type | |||||||||
Ductal NST | 63 (73.3) | 52 (60.5) | 0.392 | 47 (75.8) | 1 | - | 36 (70.6) | 1 | - |
Invasive lobular carcinoma | 7 (8.1) | 5 (5.8) | 3 (42.9) | 0.38 (0.12-1.24) | 0.109 | 4 (80.0) | 0.93 (0.33-2.62) | 0.886 | |
Other special types | 16 (18.6) | 21 (24.4) | 11 (68.7) | 0.94 (0.49-1.82) | 0.856 | 17 (81.0) | 1.32 (0.74-2.35) | 0.349 | |
Isolated cells only | 0 | 8 (9.3) | - | - | - | 4 (50.0) | 0.60 (0.21-1.69) | 0.331 | |
Histological grade | |||||||||
I | 15 (17.4) | 6 (7.0) | 0.115 | 8 (53.3) | 1 | - | 3 (50.0) | 1 | - |
II | 29 (33.7) | 31 (36.0) | 20 (69.0) | 1.91 (0.84-4.38) | 0.124 | 21 (72.4) | 1.96 (0.58-6.60) | 0.275 | |
III | 42 (48.8) | 41 (47.7) | 33 (80.5) | 2.94 (1.35-6.39) | 0.007 | 33 (82.5) | 2.98 (0.91-9.75) | 0.071 | |
Not evaluable | 0 | 8 (9.3) | - | - | - | - | |||
Tubule formation score | |||||||||
1 | 4 (4.7) | 2 (2.3) | 0.189 | 2 (50.0) | 1 | - | 1 (50.0) | 1 | - |
2 | 10 (11.6) | 17 (19.8) | 6 (60.0) | 1.33 (0.27-6.58) | 0.730 | 10 (58.8) | 1.83 (0.23-14.32) | 0.566 | |
3 | 72 (83.7) | 59 (68.6) | 53 (74.6) | 2.16 (0.52-8.89) | 0.286 | 46 (79.3) | 3.69 (0.50-26.90) | 0.198 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Nuclear pleomorphism score | |||||||||
1 | 10 (11.6) | 2 (2.3) | 0.025 | 6 (60.0) | 1 | - | 0 | 1 | - |
2 | 23 (26.7) | 20 (23.3) | 15 (65.2) | 1.70 (0.66-4.40) | 0.373 | 13 (65.0) | - (0.00-∞) | 0.889 | |
3 | 53 (61.6) | 56 (65.1) | 40 (76.9) | 2.53 (1.06-6.00) | 0.036 | 44 (78.6) | - (0.00-∞) | 0.881 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Mitotic count score | |||||||||
1 | 35 (40.7) | 32 (38.4) | 0.002 | 22 (62.9) | 1 | - | 21 (65.6) | 1 | - |
2 | 25 (29.1) | 16 (17.4) | 19 (79.2) | 2.26 (1.21-4.24) | 0.011 | 13 (81.2) | 2.12 (1.04-4.30) | 0.038 | |
3 | 26 (30.2) | 30 (34.9) | 20 (76.9) | 1.65 (0.89-3.03) | 0.109 | 23 (79.3) | 1.48 (0.81-2.67) | 0.199 | |
Not evaluable | 0 | 8 (9.3) | - | - | |||||
Tumor infiltrating inflammatory cells (%) | |||||||||
0 | 13 (15.1) | 25 (29.1) | 0.016 | 10 (76.9) | 1 | - | 18 (72.0) | 1 | - |
1 to 20 | 55 (64.0) | 49 (57.0) | 39 (70.9) | 0.83 (0.42-1.69) | 0.620 | 32 (65.3) | 0.87 (0.49-1.57) | 0.656 | |
≥ 21 | 18 (20.9) | 12 (14.0) | 12 (70.6) | 0.85 (0.37-1.98) | 0.715 | 11 (92.0) | 1.32 (0.59-2.95) | 0.503 | |
Associated in situ carcinoma | |||||||||
Present | 11 (12.8) | 29 (33.7) | < 0.001 | 5 (45.5) | 0.42 (0.17-1.07) | 0.068 | 20 (69.0) | 1.11 (0.66-1.88) | 0.682 |
Absent | 75 (87.2) | 57 (66.3) | 56 (75.7) | 41 (71.9) | |||||
Lymphovascular invasion | |||||||||
Present | 24 (27.9) | 44 (51.2) | 0.002 | 17 (70.8) | 1.26 (0.71-2.23) | 0.422 | 36 (81.8) | 1.90 (1.12-3.19) | 0.016 |
Absent | 62 (72.1) | 42 (48.8) | 44 (72.1) | 25 (61.0) | |||||
Estrogen receptor status | |||||||||
Negative | 38 (44.2) | 49 (57.0) | 0.003 | 32 (86.5) | 0.35 (0.21-0.58) | < 0.001 | 40 (83.3) | 0.39 (0.23-0.67) | < 0.001 |
Positive | 48 (55.8) | 37 (43.0) | 29 (60.4) | 21 (56.8) | |||||
Progesterone receptor status | |||||||||
Negative | 46 (53.5) | 57 (66.3) | 0.019 | 38 (84.4) | 0.37 (0.20-0.63) | < 0.001 | 43 (76.8) | 0.57 (0.32-0.98) | 0.044 |
Positive | 40 (46.5) | 29 (33.7) | 23 (57.5) | 18 (62.1) | |||||
HER2 expression | |||||||||
Negative | 75(87.2) | 76 (88.4) | 0.051 | 54 (73.0) | 1.08 (0.49-2.38) | 0.842 | 54 (72.0) | 1.21 (0.55-2.67) | 0.632 |
Positive | 11(12.8) | 10 (11.6) | 7 (63.6) | 7 (70.0) | |||||
Ki67 expression | |||||||||
Low | 44 (51.2) | 62 (72.1) | 0.003 | 26 (60.5) | 2.47 (1.47-4.15) | 0.001 | 41 (66.1) | 1.68 (0.98-2.87) | 0.06 |
High | 42 (48.8) | 24 (27.9) | 35 (83.3) | 20 (87.0) | |||||
IHC profile | |||||||||
Luminal A–like | 18 (20.9) | 26 (30.2) | < 0.001 | 10 (55.6) | 1 | - | 11 (42.3) | 1 | - |
Luminal B–like | 30 (34.9) | 12 (14.0) | 19 (63.3) | 1.12 (0.57-2.65) | 0.595 | 10 (83.3) | 2.58 (1.09-6.13) | 0.031 | |
HER2-positive | 7 (8.1) | 6 (7.0) | 4 (57.1) | 1.25 (0.39-4.01) | 0.712 | 3 (50.0) | 2.03 (0.56-7.30) | 0.279 | |
Triple-negative | 31 (36.0) | 42 (48.8) | 28 (93.3) | 4.45 (2.12-9.32) | < 0.001 | 37 (88.1) | 4.52 (2.29-8.92) | < 0.001 |
Tumor behavior | No. (%) | Type | No. of total of cases (%) | No. of changes (%) |
---|---|---|---|---|
Histological type | ||||
Stable | 59 (68.6) | Ductal NST to lobular | 1 (1.2) | 1 (5.3) |
Changed | 19 (22.1) | Ductal NST to special types | 10 (11.6) | 10 (52.6) |
Isolated cells | 8 (9.3) | Lobular to special types | 2 (2.3) | 2 (10.5) |
Special types to ductal NST | 5 (5.8) | 5 (26.3) | ||
Special types to lobular | 1 (1.2) | 1 (5.3) | ||
Histological grade | ||||
Stable | 47 (54.6) | Higher to lower | 10 (11.6) | 10 (32.3) |
Changed | 31 (36.1) | Lower to higher | 21 (24.5) | 21 (67.7) |
NE | 8 (9.3) | |||
Tubular formation | ||||
Stable | 65 (75.6) | Higher to lower | 8 (9.3) | 8 (61.5) |
Changed | 13 (15.1) | Lower to higher | 5 (5.8) | 5 (38.5) |
NE | 8 (9.3) | |||
Nuclear pleomorphism | ||||
Stable | 53 (61.6) | Higher to lower | 5 (5.8) | 5 (20.0) |
Changed | 25 (29.1) | Lower to higher | 20 (23.2) | 20 (80.0) |
NE | 8 (9.3) | |||
Mitotic count | ||||
Stable | 41 (47.7) | Higher to lower | 16 (18.5) | 16 (43.2) |
Changed | 37 (43.0) | Lower to higher | 21 (24.4) | 21 (56.8) |
NE | 8 (9.3) | |||
Inflammatory infiltrate | ||||
Stable | 43 (50.0) | Higher to lower | 31 (36.0) | 31 (72.0) |
Changed | 43 (50.0) | Lower to higher | 12 (14.0) | 12 (28.0) |
Presence of in situ carcinoma | ||||
Stable | 62 (72.1) | Absent to present | 21 (24.4) | 21 (87.5) |
Changed | 24 (27.9) | Present to absent | 3 (3.5) | 3 (12.5) |
Lymphovascular invasion | ||||
Stable | 48 (55.8) | Absent to present | 29 (33.7) | 29 (76.3) |
Changed | 38 (44.2) | Present to absent | 9 (10.5) | 9 (23.7) |
Estrogen receptor status | ||||
Stable | 73 (84.9) | Positive to negative | 12 (14.0) | 12 (92.3) |
Changed | 13 (15.1) | Negative to positive | 1 (1.2) | 1 (7.7) |
Progesterone receptor status | ||||
Stable | 67 (77.9) | Positive to negative | 15 (17.4) | 15 (78.9) |
Changed | 19 (22.1) | Negative to positive | 4 (4.7) | 4 (21.1) |
HER2 expression | ||||
Stable | 84 (94.7) | Positive to negative | 2 (2.3) | 2 (100) |
Changed | 2 (5.3) | Negative to positive | 0 ( | 0 ( |
HER2 expression (categories) | ||||
Stable | 73 (84.9) | 0 to 1+ | 1 (1.2) | 1 (7.7) |
Changed | 13 (15.1) | 1+ to 0 | 8 (9.3) | 8 (61.5) |
2+ to 0 | 2 (2.3) | 2 (15.4) | ||
3+ to 1+ | 1 (1.2) | 1 (7.7) | ||
3+ to 2+ | 1 (1.2) | 1 (7.7) | ||
Ki67 expression | ||||
Stable | 52 (60.5) | Low to high | 8 (9.3) | 8 (23.5) |
Changed | 34 (39.5) | High to low | 26 (30.2) | 26 (76.5) |
IHC subtype | ||||
Stable | 60 (69.8) | Luminal A–like to B | 1 (1.2) | 1 (3.8) |
Changed | 26 (30.2) | Luminal A–like to TN | 3 (3.5) | 3 (11.5) |
Luminal B to A | 12 (14.0) | 12 (46.2) | ||
Luminal B to HER2 | 1 (1.2) | 1 (3.8) | ||
Luminal B to TN | 7 (8.1) | 7 (26.9) | ||
HER2 to luminal B–like | 1 (1.2) | 1 (3.8) | ||
HER2 to TN | 1 (1.2) | 1 (3.8) |
Included parameter | Final step |
|
---|---|---|
HR (95% CI) | p-value |
|
Pre-NACT | ||
Age at diagnosis | - | - |
Histological grade | ||
I | 1 | - |
II | 1.87 (0.79-4.39) | 0.152 |
III | 2.71 (1.16-6.31) | 0.021 |
IHC profile | ||
Luminal A-like | 1 | - |
Luminal B-like | 0.91 (0.41-2.04) | 0.823 |
HER2-like | 0.73 (0.21-2.50) | 0.618 |
Triple-negative | 3.32 (1.52-7.27) | 0.003 |
Post-NACT | ||
Age at diagnosis | - | - |
Presence of lymphovascular invasion | - | - |
Histological grade | ||
I | - | - |
II | - | - |
III | - | - |
IHC profile | ||
Luminal A–like | 1 | - |
Luminal B–like | 2.26 (0.95-5.35) | 0.065 |
HER2-like | 2.06 (0.45-9.35) | 0.349 |
Triple-negative | 4.39 (2.20-8.77) | < 0.001 |
CI, confidence interval; NACT, neoadjuvant chemotherapy; SD, standard deviation. p-values calculated by Cox proportional hazards model.
Survival analysis refers to the 85 cases with available survival data. CI, confidence interval; Ductal NST, invasive carcinoma of no special type; HER2, human epidermal growth factor receptor 2; IHC profile, immunohistochemmichal profile; NACT, neoadjuvant chemotherapy. p-value calculated by Mc-Nemar, Mc-Nemar-Bowker, Wilcoxon and Cox proportional hazards model.
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemical; NACT, neoadjuvant chemotherapy; NE, not evaluable; NST, no special type; TN, triple-negative.
CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC profile, immunohistochemical profile; NACT, neoadjuvant chemotherapy. p-values, calculated by Cox proportional hazards model.